Education
About Us
Working with TipRanks
Follow Us
Pulse Biosciences (PLSE)
NASDAQ:PLSE
Earnings Data
Report Date
Aug 06, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
―Last Year’s EPS
-0.2Same Quarter Last Year
Based on 0 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 08, 2025
|% Change Since: 2.02%
|Next Earnings Date:Aug 06, 2025
Earnings Call Sentiment|Positive
The earnings call highlights significant advancements in clinical trials, FDA approvals, and cash position, indicating robust progress in technology and market penetration. However, the increased operating expenses and cash usage present challenges that need addressing.Company Guidance
During the Pulse Biosciences First Quarter 2025 Financial Results Conference Call, CEO Paul LaViolette highlighted the company's strategic focus on advancing Nanosecond Pulsed Field Ablation (nsPFA) technology and its applications across various medical fields. The company achieved significant milestones, such as treating over 6,000 patients and obtaining FDA breakthrough device designation for its cardiac surgical clamp. Priorities for 2025 include the commercialization of a percutaneous electrode for soft tissue ablation in benign thyroid disease and initiating IDE pivotal studies for their Cardiac 360 catheter and cardiac surgical clamp. Financially, Pulse Biosciences reported a GAAP net loss of $16.8 million for Q1 2025, with cash and cash equivalents totaling $119.3 million as of March 31, 2025. The company raised $14 million through warrant exercises, maintaining its cash position similar to year-end 2024. These developments reflect the company's commitment to transforming patient care through innovative therapies.FDA Clearances and Breakthrough Device Designation
Pulse Biosciences has obtained seven FDA clearances and received a breakthrough device designation for their cardiac surgical clamp, indicating strong validation of their technology.
Successful Clinical Trials
Clinical trials for the nsPFA 360 catheter demonstrated excellent procedure efficiency and acute outcomes, with 130 AF patients treated in European clinical feasibility studies.
Positive Outcomes for Thyroid Nodule Treatment
The nsPFA percutaneous electrode achieved an average 83% volume reduction in thyroid nodules at one year, with significant symptom reductions one month post-treatment.
Increased Cash Position
The company raised $14 million through the exercise of warrants, increasing cash and cash equivalents to $119.3 million as of March 31, 2025.
Encouraging Cardiac Catheter System Results
The 360 cardiac catheter system showed a 94.2% success rate for pulmonary vein isolation and a 95.5% success rate for left atrial posterior wall isolation.
---
PLSE Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
PLSE Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 08, 2025 | $16.85 | $17.07 | +1.31% |
Mar 27, 2025 | $15.66 | $16.60 | +6.00% |
Oct 30, 2024 | $17.72 | $17.43 | -1.64% |
Aug 12, 2024 | $15.65 | $16.91 | +8.05% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Pulse Biosciences (PLSE) report earnings?
Pulse Biosciences (PLSE) is schdueled to report earning on Aug 06, 2025, TBA Not Confirmed.
What is Pulse Biosciences (PLSE) earnings time?
Pulse Biosciences (PLSE) earnings time is at Aug 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PLSE EPS forecast?
Currently, no data Available
---